BioLineRx Prices Public Offering Of 8.40 Mln ADSs At $2.50/ADS - Quick Facts

(RTTNews) - BioLineRx (BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced that it has priced an underwritten public offering of 8.40 million American Depositary Shares or "ADSs", each representing ten of its Ordinary Shares, at a public offering price of $2.50 per ADS for gross proceeds of $21.0 million.

All of the ADSs in the offering are to be sold by BioLineRx. Delivery of the ADSs is expected to occur on March 7, 2014.

The company stated that it has granted the underwriters a 30-day option to purchase up to an additional 1.26 million ADSs to cover over-allotments, if any.

Roth Capital Partners acted as sole book-running manager for the offering. Maxim Group LLC acted as co-manager.